--- title: Thomas Smeenk description: Thomas A. Smeenk, President & CEO of Hemostemix, leads innovations in regenerative medicine with patient-derived therapies for critical limb ischemia and peripheral arterial disease. --- [![Hemostemix Logos](https://hemostemix.com/hubfs/Hemostemix%20Logos.png)](https://hemostemix.com?hsLang=en) - [Patient Information](https://hemostemix.com/investigational-treatment-options) - [Physician Information](https://hemostemix.com/physicians) - ACP-01 Show submenu for ACP-01 - [ACP-01](https://hemostemix.com/acp-autologous-stem-cell-therapy) - [Clinical Research](https://hemostemix.com/clinical-research) - Conditions Show submenu for Conditions - [Cardiovascular Ischemia & Angina](https://hemostemix.com/cardiovascular-ischemia-angina) - [Chronic Limb Ischemia - CLTI](https://hemostemix.com/chronic-limb-threatening-ischemia) - [Peripheral Arterial Disease- PAD](https://hemostemix.com/peripheral-arterial-disease-pad-and-peripheral-ischemia) - [Vascular Dementia](https://hemostemix.com/vascular-dementia) - [Wound Care](https://hemostemix.com/wound-care) - [Chronic Neuropathic and Ischemic Pain](https://hemostemix.com/chronic-neuropathic-and-ischemic-pain) - [Events & Replays](https://hemostemix.com/events) - Blog Show submenu for Blog - [Hemostemix Health Hub](https://hemostemix.com/health-hub-blog) - [Hemostemix Video Library](https://hemostemix.com/videolibrary) - [About](https://hemostemix.com/about) - [Patient Information](https://hemostemix.com/investigational-treatment-options) - [Physician Information](https://hemostemix.com/physicians) - ACP-01 Show submenu for ACP-01 - [ACP-01](https://hemostemix.com/acp-autologous-stem-cell-therapy) - [Clinical Research](https://hemostemix.com/clinical-research) - Conditions Show submenu for Conditions - [Cardiovascular Ischemia & Angina](https://hemostemix.com/cardiovascular-ischemia-angina) - [Chronic Limb Ischemia - CLTI](https://hemostemix.com/chronic-limb-threatening-ischemia) - [Peripheral Arterial Disease- PAD](https://hemostemix.com/peripheral-arterial-disease-pad-and-peripheral-ischemia) - [Vascular Dementia](https://hemostemix.com/vascular-dementia) - [Wound Care](https://hemostemix.com/wound-care) - [Chronic Neuropathic and Ischemic Pain](https://hemostemix.com/chronic-neuropathic-and-ischemic-pain) - [Events & Replays](https://hemostemix.com/events) - Blog Show submenu for Blog - [Hemostemix Health Hub](https://hemostemix.com/health-hub-blog) - [Hemostemix Video Library](https://hemostemix.com/videolibrary) - [About](https://hemostemix.com/about) ![menu](https://f.hubspotusercontent40.net/hubfs/7479797/menu.png) ![close\_24px](https://7479797.fs1.hubspotusercontent-na1.net/hubfs/7479797/close_24px.svg) [Investor Site](https://investors.hemostemix.com/?hsLang=en) ![Hemostemix-Tom](https://hemostemix.com/hubfs/Hemostemix-Tom.jpeg) ###### Thomas A. Smeenk, BA President & CEO. Co-Founder Ask Thomas Smeenk, CEO, Hemostemix Inc. (TSXV: HEM | OTCQB: HMTXF), about investment opportunities, or if you're eligible for treatment in CANADA, The Bahamas or Florida. Backed by 498 treatments, including the clinical trial data of 318 subjects detailed in 11 peer-reviewed publications, ACP-01 has been shown to be safe, efficacious, and clinically relevant as a treatment for cardiovascular diseases of the heart, limb - PAD - and brain - vascular dementia. VesCell (ACP-01) is still under investigation and is not FDA or Health Canada approved. Individual results may vary. [Book a Meeting](https://hemostemix.com/meetings/thomas-smeenk?hsLang=en) [![LOGO\_Primary](https://hemostemix.com/hubfs/LOGO_Primary.png)](https://hemostemix.com?hsLang=en) Leave us a message Follow Us Copyright © 2026 Hemostemix, Inc [Privacy Policy |](https://hemostemix.com/privacy-policy?hsLang=en) [Terms of Service](https://hemostemix.com/sms-terms-of-service?hsLang=en)